Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept Effects on Peripheral Immune Cell Subsets in Lupus Nephritis
ChiCTR2500095088Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept in lupus nephritis (LN) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Peripheral blood T/B cell subsets, Routine blood test and 4 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on ChiCTR2500095088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095088.